Castelvecchio Pascoli (Lucca, Italy), July 12 2021 – Kedrion S.p.A., announced that Friday 9th has closed the purchase of Prometic Bioproduction Inc. (“PBP”), a former subsidiary of Liminal BioSciences and the operator of a manufacturing facility (the “First Closing”), which is the first in a planned series of two related closings. The price paid to Liminal for PBP was USD 5 million, subject to certain adjustments.
Kedrion SpA will also be entitled to receive 30% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher (“PRV”) by Prometic Biotherapeutics Inc. (“PBT”), which would be payable upon closing of the second transaction in the series, the acquisition of PBT (the “Second Closing”). PBT is the holder of the biological license application (“BLA”) for Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.
Plasminogen is a protein synthesized by the liver and circulates in the blood. Activated plasminogen, plasmin, is a fundamental component of the fibrinolytic system and is the main enzyme involved in the lysis of blood clots and clearance of extravasated fibrin. Plasminogen is therefore vital in wound healing, cell migration, tissue remodeling, angiogenesis, and embryogenesis.
Kedrion Biopharma is an international biopharmaceutical company based in Italy that collects and fractionates plasma to produce and distribute worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as Hemophilia, Primary Immunodeficiencies and Rh sensitization.
Headquartered in Tuscany with more than 2,500 employees worldwide, Kedrion has a commercial presence in 100 countries and is the 5th largest player in the world, and Italy’s 1st.
Kedrion has manufacturing plants in Italy, Hungary and North America, and its subsidiary KEDPLASMA operates plasma collection centers in North America.
Kedrion acts as a bridge between donors and the people who need treatments and works on a global scale to expand patient access to available plasma-derived therapies.